Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has announced it will host a conference call on February 27, 2025, at 8 a.m. ET to discuss its fourth quarter and full-year 2024 financial results and operational highlights.
U.S. participants can dial 1-833-316-0545, while international callers should use 1-412-317-5726. A live webcast will be available, and a replay will be accessible through the company's website starting at 12 p.m. ET on the same day.
Intellia Therapeutics (NASDAQ:NTLA), un'azienda in fase clinica specializzata in terapie basate su CRISPR, ha annunciato che ospiterà una conferenza telefonica il 27 febbraio 2025, alle 8:00 ET per discutere i risultati finanziari del quarto trimestre e dell'intero anno 2024 e i punti salienti operativi.
I partecipanti statunitensi possono comporre il numero 1-833-316-0545, mentre i chiamanti internazionali dovrebbero utilizzare il numero 1-412-317-5726. Sarà disponibile una webcast in diretta e una registrazione sarà accessibile attraverso il sito web dell'azienda a partire dalle 12:00 ET dello stesso giorno.
Intellia Therapeutics (NASDAQ:NTLA), una empresa de edición genética en etapa clínica especializada en terapias basadas en CRISPR, ha anunciado que llevará a cabo una conferencia telefónica el 27 de febrero de 2025, a las 8:00 a.m. ET para discutir sus resultados financieros del cuarto trimestre y del año completo 2024 y los aspectos destacados operativos.
Los participantes de EE. UU. pueden marcar 1-833-316-0545, mientras que los llamantes internacionales deben usar 1-412-317-5726. Habrá una transmisión web en vivo disponible, y una repetición estará accesible a través del sitio web de la empresa a partir de las 12:00 p.m. ET del mismo día.
Intellia Therapeutics (NASDAQ:NTLA)는 CRISPR 기반 치료법을 전문으로 하는 임상 단계 유전자 편집 회사로, 2025년 2월 27일 오전 8시 ET에 2024년 4분기 및 연간 재무 결과와 운영 하이라이트를 논의하기 위한 컨퍼런스 콜을 개최한다고 발표했습니다.
미국 참가자는 1-833-316-0545로 전화할 수 있으며, 국제 전화자는 1-412-317-5726을 사용해야 합니다. 생중계 웹캐스트가 제공되며, 같은 날 정오 ET부터 회사 웹사이트를 통해 재생이 가능합니다.
Intellia Therapeutics (NASDAQ:NTLA), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies basées sur CRISPR, a annoncé qu'elle tiendra une conférence téléphonique le 27 février 2025 à 8h00 ET pour discuter de ses résultats financiers du quatrième trimestre et de l'année complète 2024 ainsi que des points saillants opérationnels.
Les participants aux États-Unis peuvent composer le 1-833-316-0545, tandis que les appelants internationaux doivent utiliser le 1-412-317-5726. Un webinaire en direct sera disponible, et un enregistrement sera accessible sur le site Web de l'entreprise à partir de 12h00 ET le même jour.
Intellia Therapeutics (NASDAQ:NTLA), ein klinisches Unternehmen für Genbearbeitung, das sich auf CRISPR-basierte Therapien spezialisiert hat, hat angekündigt, am 27. Februar 2025 um 8:00 Uhr ET eine Telefonkonferenz abzuhalten, um die Finanzergebnisse des vierten Quartals und des Gesamtjahres 2024 sowie betriebliche Höhepunkte zu besprechen.
Teilnehmer aus den USA können 1-833-316-0545 wählen, während internationale Anrufer 1-412-317-5726 verwenden sollten. Es wird eine Live-Webcast geben, und eine Aufzeichnung wird ab 12:00 Uhr ET am selben Tag über die Website des Unternehmens verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2024 financial results and operational highlights in a conference call on February 27, 2025, at 8 a.m. ET.
To join the call:
- U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
- Please visit this link for a simultaneous live webcast of the call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on February 27, 2025, at 12 p.m. ET.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
brittany.chaves@intelliatx.com
FAQ
When will Intellia Therapeutics (NTLA) report Q4 and full-year 2024 earnings?
How can investors access Intellia Therapeutics' (NTLA) Q4 2024 earnings call?
Will there be a replay available for Intellia's (NTLA) Q4 2024 earnings call?
What topics will be covered in Intellia's (NTLA) Q4 2024 earnings call?
